Physician profile
Thomas E Lalonde
NPI 1548252687
$2,120.84
in general payments reported to CMS, 2019-2025
12 companies · $357 in 2025
The $357 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $452 · 2020: $150 · 2021: $183 · 2022: $301 · 2023: $508 · 2024: $169 · 2025: $357.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,034.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,034.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $688.76 | 2021-2025 | Hydrus Microstent, Voyager Dslt, Total30 |
| Johnson & Johnson Vision Care, INC. | $469.26 | 2019-2025 | Acuvue |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $165.29 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $150.63 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $140.01 | 2022-2025 | Infuse, Vyzulta |
| Visioneering Technologies, INC. | $125.74 | 2022 | |
| Johnson & Johnson Surgical Vision, INC. | $102.95 | 2019 | |
| Sun Pharmaceutical Industries INC. | $101.08 | 2020 | |
| Apellis Pharmaceuticals, INC. | $83.51 | 2023 | Syfovre |
| Janssen Pharmaceuticals, INC | $50.71 | 2022-2023 | Acuvue |
| Derma Sciences, INC. | $21.82 | 2019 | |
| Coopervision INC. | $21.08 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Lalonde listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.